title: Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats.
abstract: 1. The novel phosphodiesterase (PDE) inhibitor SCA40 (6-bromo-8(methylamino)imidazo[1,2-a]pyrazine-2-carbonitrile) was examined for its vasorelaxant activity on isolated pulmonary vascular preparations from rats. 2. SCA40 relaxed ring preparations of main and intralobar pulmonary artery precontracted submaximally with either phenylephrine or U46619 (thromboxane-mimetic). Based on negative log EC50 values, SCA40 was six-to 14-fold more potent than the PDE III inhibitor milrinone or the non-selective PDE inhibitor 3-isobutyl-1-methyl xanthine (IBMX). The potency of SCA40 corresponded to its reported potency as a PDE III inhibitor. 3. In isolated perfused lungs, SCA40 reversed the vasoconstriction induced by alveolar hypoxia. It was 49-fold more potent than IBMX. 4. In main pulmonary artery the vasorelaxation induced by SCA40 was not blocked by the large-conductance calcium-activated potassium channel (BKCa) inhibitors iberiotoxin (50 and 100 nmol/L) or charybdotoxin (100 and 300 nmol/L). This was in contrast to data on guinea-pig trachea, where responses to SCA40 were significantly inhibited by charybdotoxin (100 nmol/L). 5. It is concluded that opening of BKCa channels does not contribute to the pulmonary vasorelaxant effects of SCA40 in main pulmonary artery and it is likely that responses reflect the PDE III inhibitory properties of the drug. 6. It is postulated that SCA40 may be useful as a pulmonary vasodilator in disorders such as pulmonary hypertension.
authors.affiliation: Department of Physiology and Pharmacology, University of Queensland, St Lucia, Australia.
authors.forename: T K
authors.initials: TK
authors.lastname: Crilley
authors.forename: J C
authors.initials: JC
authors.lastname: Wanstall
authors.forename: P A
authors.initials: PA
authors.lastname: Bonnet
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006168:Guinea Pigs; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D020105:Milrinone; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010276:Parasympatholytics / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D026902:Potassium Channel Blockers; D011651:Pulmonary Artery / Q000187:drug effects*; D011719:Pyrazines / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014132:Trachea / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D007093:Imidazoles; D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D026902:Potassium Channel Blockers; D011719:Pyrazines; D011728:Pyridones; D014665:Vasodilator Agents; C080660:6-bromo-8-methylaminoimidazo(1,2-a)pyrazine-2-carbonitrile; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D020105:Milrinone; D015056:1-Methyl-3-isobutylxanthine